Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanoma.

Ahamadi, Malidi; Kast, Johannes; Chen, Po-Wei; Huang, Xiaojun; Dutta, Sandeep; Upreti, Vijay V

Ahamadi, Malidi; Kast, Johannes; Chen, Po-Wei; Huang, Xiaojun; Dutta, Sandeep; Upreti, Vijay V.

Afiliação

Ahamadi M; Clinical Pharmacology Modeling and Simulation, Amgen Inc, Thousand Oaks, California, USA.
Kast J; Clinical Pharmacology Modeling and Simulation, Amgen Inc, South San Francisco, California, USA.
Chen PW; Clinical Pharmacology Modeling and Simulation, Amgen Inc, Thousand Oaks, California, USA.
Huang X; Global Development, Amgen Inc, Thousand Oaks, California, USA.
Dutta S; Clinical Pharmacology Modeling and Simulation, Amgen Inc, Thousand Oaks, California, USA.
Upreti VV; Clinical Pharmacology Modeling and Simulation, Amgen Inc, South San Francisco, California, USA.

CPT Pharmacometrics Syst Pharmacol ; 12(2): 250-260, 2023 02.

Article em En | MEDLINE | ID: mdl-36564918

Assuntos

Melanoma; Terapia Viral Oncolítica; Vírus Oncolíticos; Neoplasias Cutâneas; Humanos; Imunoterapia/métodos; Cinética; Melanoma/tratamento farmacológico; Distribuição Tecidual

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Vírus Oncolíticos / Terapia Viral Oncolítica / Melanoma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google